Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
J Urol
    December 2024
  1. CANFIELD SE, George AK, Jue JS, Lewis SC, et al
    A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation.
    J Urol. 2024;212:862-872.
    >> Share

  2. FLEVILLE S, O'Neill C, Safar D, Macleod A, et al
    Diagnostic Pathway Outcomes for Biparametric Magnetic Resonance Imaging-Targeted Lesions Using Cognitive Registration and Freehand Transperineal Prostate Biopsy in Biopsy-Naive Men (CRAFT Single-Center Study).
    J Urol. 2024;212:821-831.
    >> Share

    November 2024
  3. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    High 11-ketotestosterone linked to shorter time to castration resistance in recurrent non-metastatic prostate cancer.
    J Urol. 2024 Nov 15:101097JU0000000000004333. doi: 10.1097/JU.0000000000004333.
    >> Share

  4. NABI R, Zahid T, Farooqi HA
    Letter: Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by (18)F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Cente
    J Urol. 2024;212:762-763.
    >> Share

    October 2024
  5. FILON M, O'Neil B
    Can We Be Less Active in Prostate Cancer Surveillance?
    J Urol. 2024 Oct 16:101097JU0000000000004277. doi: 10.1097/JU.0000000000004277.
    >> Share

  6. FAKUNLE MO, Cowan JE, Washington SL 3rd, Shinohara K, et al
    Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer.
    J Urol. 2024 Oct 9:101097JU0000000000004265. doi: 10.1097/JU.0000000000004265.
    >> Share

  7. BHANJI Y, Mamawala MK, Fletcher SA, Landis P, et al
    Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging?
    J Urol. 2024 Oct 2:101097JU0000000000004268. doi: 10.1097/JU.0000000000004268.
    >> Share

  8. MA C
    Letter: Location-Based Oncological Outcomes of Sentinel Node Dissection in Radical Prostatectomy.
    J Urol. 2024;212:627-628.
    >> Share

  9. YAXLEY JW
    Letter: Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
    J Urol. 2024;212:628.
    >> Share

  10. CHOUDRY MM, Durant AM, Edmonds VS, Warren CJ, et al
    Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.
    J Urol. 2024;212:590-599.
    >> Share

    September 2024
  11. FLORES JM, Vertosick EA, Salter CA, Benfante N, et al
    Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004267. doi: 10.1097/JU.0000000000004267.
    >> Share

  12. STONE BV, Dominas CA, Bhagavatula SK, Ahn SW, et al
    Novel intraprostatic MR-guided implantation of multidrug-eluting microdevice for testing of systemic therapy agents in situ; Proof of concept in intermediate- and high-risk prostate cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004269. doi: 10.1097/JU.0000000000004269.
    >> Share

  13. CARLSSON SV, Carroll PR, Hamdy FC
    Reevaluating the Definition of "Clinically Significant" Prostate Cancer as Grade Groups 2-5: An Imperative for Improved Risk Stratification.
    J Urol. 2024 Sep 17:101097JU0000000000004253. doi: 10.1097/JU.0000000000004253.
    >> Share

  14. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2024 Sep 16:101097JU0000000000004239. doi: 10.1097/JU.0000000000004239.
    >> Share

  15. SHORE ND, De Giorgi U, Freedland SJ
    Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.
    J Urol. 2024 Sep 3:101097JU0000000000004228. doi: 10.1097/JU.0000000000004228.
    >> Share

  16. GAFFNEY CD, Vertosick EA, Laudone V, Goh AC, et al
    Randomized Trial of Transverse vs Vertical Extraction Site Incision After Robotic Radical Prostatectomy.
    J Urol. 2024;212:401-408.
    >> Share

  17. KLOTZ L
    The Genomics and Natural History of MRI-Visible vs MRI-Invisible Prostate Cancers: Clinical Implications.
    J Urol. 2024;212:494-498.
    >> Share

  18. MIAN BM, Kaufman RP Jr, Berstein A, Fisher HAG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;212:511-512.
    >> Share

  19. DROGHETTI M, Ozman O, Berrens AC, Piazza P, et al
    Location-Based Oncological Outcomes of Sentinel Node Dissection in Radical Prostatectomy.
    J Urol. 2024;212:409-419.
    >> Share

  20. ZILLIOUX J, Camacho FT, Anderson RT, You W, et al
    Prevalence of Cognitive and Manual Dexterity Disorders Among Men Following Artificial Urinary Sphincter Placement.
    J Urol. 2024;212:441-450.
    >> Share

    August 2024
  21. SUN R, Shan D
    Letter: Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2024 Aug 23:101097JU0000000000004215. doi: 10.1097/JU.0000000000004215.
    >> Share

  22. BAHLER CD
    Reply: Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 Aug 12:101097JU0000000000004170. doi: 10.1097/JU.0000000000004170.
    >> Share

  23. SHORE N, Pieczonka C, Heron S, Gazi M, et al
    Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
    J Urol. 2024 Aug 9:101097JU0000000000004190. doi: 10.1097/JU.0000000000004190.
    >> Share

  24. NIU S, Ding X, Liu B, Ao L, et al
    Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by (18)F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prosp
    J Urol. 2024;212:280-289.
    >> Share

  25. VICKERS A, Vertosick E, Langsetmo L, Dahm P, et al
    Estimating the Effect of Radical Prostatectomy: Combining Data From the SPCG4 and PIVOT Randomized Trials With Contemporary Cohorts.
    J Urol. 2024;212:310-319.
    >> Share

  26. SHORE N, Hafron J, Saltzstein D, Brown G, et al
    Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).
    J Urol. 2024 Aug 1:101097JU0000000000004163. doi: 10.1097/JU.0000000000004163.
    >> Share

    July 2024
  27. LENI R, Vickers AJ, Brasso K, Montorsi F, et al
    Management and Oncologic Outcomes of Incidental Prostate Cancer After Transurethral Resection of the Prostate in Denmark.
    J Urol. 2024 Jul 31:101097JU0000000000004159. doi: 10.1097/JU.0000000000004159.
    >> Share

  28. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
    Letter: Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Jul 31:101097JU0000000000004171. doi: 10.1097/JU.0000000000004171.
    >> Share

  29. CIRULLI GO, Davis M, Stephens A, Chiarelli G, et al
    Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis.
    J Urol. 2024 Jul 30:101097JU0000000000004118. doi: 10.1097/JU.0000000000004118.
    >> Share

  30. ROY S, Sun Y, Chi KN, Ong M, et al
    Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial.
    J Urol. 2024 Jul 26:101097JU0000000000004158. doi: 10.1097/JU.0000000000004158.
    >> Share

  31. MAI Z, Yan W
    Letter: Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 Jul 25:101097JU0000000000004155. doi: 10.1097/JU.0000000000004155.
    >> Share

  32. GIESEN A, Devos G, Everaerts W, Joniau S, et al
    Letter: A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024 Jul 8:101097JU0000000000004127. doi: 10.1097/JU.0000000000004127.
    >> Share

  33. RIVIERE P, Deshler LN, Morgan KM, Qiao EM, et al
    PSA Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age-Limits for Recommended Screening.
    J Urol. 2024 Jul 5:101097JU0000000000004138. doi: 10.1097/JU.0000000000004138.
    >> Share

  34. MOTA SM, Priester A, Shubert J, Bong J, et al
    Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.
    J Urol. 2024;212:52-62.
    >> Share

  35. MIAN BM, Bernstein A, Kaufman RP Jr, Fisher HAG, et al
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;212:227-228.
    >> Share

  36. NAHAS WC, Rodrigues GJ, Rodrigues Goncalves FA, Sawczyn GV, et al
    Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
    J Urol. 2024;212:32-40.
    >> Share

  37. TILL C, Goodman PJ, Tangen C, Lucia MS, et al
    Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention Trial.
    J Urol. 2024;212:228-229.
    >> Share

    June 2024
  38. NANDALUR KR, Shen C, Zhao L, Al-Katib S, et al
    Association of Baseline MRI PI-RADS Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    J Urol. 2024 Jun 25:101097JU0000000000004117. doi: 10.1097/JU.0000000000004117.
    >> Share

  39. LEWICKI P, Morgan T
    The Genomics and Natural History of MRI Visible vs. Invisible Prostate Cancer: Clinical Implications".
    J Urol. 2024 Jun 12:101097JU0000000000004104. doi: 10.1097/JU.0000000000004104.
    >> Share

  40. MOSES RA, Hunter AE, Brandes ER, Zhang Z, et al
    Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy.
    J Urol. 2024;211:765-774.
    >> Share

  41. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:802-803.
    >> Share

  42. SZABO RJ
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:801-802.
    >> Share

    May 2024
  43. BAHLER CD, Tachibana I, Tann M, Collins K, et al
    Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 May 24:101097JU0000000000004032. doi: 10.1097/JU.0000000000004032.
    >> Share

  44. HUSSAIN J, Sanchez-Salas R
    Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2024 May 19:101097JU0000000000003924. doi: 10.1097/JU.0000000000003924.
    >> Share

  45. EMMETT L, Papa N, Hope TA, Fendler W, et al
    Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
    J Urol. 2024 May 17:101097JU0000000000004010. doi: 10.1097/JU.0000000000004010.
    >> Share

  46. TRINH QD, Labban M, Daniels D, Feldman A, et al
    Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color.
    J Urol. 2024 May 4:101097JU0000000000003931. doi: 10.1097/JU.0000000000003931.
    >> Share

  47. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.
    J Urol. 2024 May 3:101097JU0000000000003979. doi: 10.1097/JU.0000000000003979.
    >> Share

  48. QIAN H, Chi C, Tricard T, Zhu Y, et al
    A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024;211:648-655.
    >> Share

  49. MARIOTTI GC, Schmid BP, Gilberto GM, Garcia RG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707.
    >> Share

  50. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707-708.
    >> Share

    April 2024
  51. ST-LAURENT MP, Acland G, Hamilton SN, Hamm J, et al
    Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy.
    J Urol. 2024 Apr 11:101097JU0000000000003965. doi: 10.1097/JU.0000000000003965.
    >> Share

  52. RUMPF F, Plym A, Vaselkiv JB, Penney KL, et al
    Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Apr 10:101097JU0000000000003927. doi: 10.1097/JU.0000000000003927.
    >> Share

  53. URABE F, Yoshioka T, Tashiro K, Kimura T, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:622.
    >> Share

  54. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:623-624.
    >> Share

  55. CAKICI MC, Ozgur Kazan H, Yildirim A
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:624-625.
    >> Share

    March 2024
  56. LOEB S, Sanchez Nolasco T, Byrne N, Allen L, et al
    Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer.
    J Urol. 2024;211:376-383.
    >> Share

  57. FLORES JM, Vertosick E, Jenkins LC, Cooper J, et al
    Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
    J Urol. 2024;211:400-406.
    >> Share

  58. MANNAS MP, Deng FM, Ion-Margineanu A, Jones D, et al
    Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies.
    J Urol. 2024;211:384-391.
    >> Share

  59. HOUGEN HY, Sjoberg DD, Thomas J, Mahal BA, et al
    Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.
    J Urol. 2024;211:392-399.
    >> Share

  60. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2024;211:502-503.
    >> Share

    February 2024
  61. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2024 Feb 19:101097JU0000000000003892. doi: 10.1097/JU.0000000000003892.
    >> Share

  62. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
    J Urol. 2024 Feb 14:101097JU0000000000003890. doi: 10.1097/JU.0000000000003890.
    >> Share

  63. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
    J Urol. 2024 Feb 14:101097JU0000000000003891. doi: 10.1097/JU.0000000000003891.
    >> Share

  64. ESCOBAR AJ, Krishna S, Flowers KM, Abello A, et al
    Practical Use of Self-Adjusted Nitrous Oxide During Transrectal Prostate Biopsy: A Double-Blind Randomized Controlled Trial.
    J Urol. 2024;211:214-222.
    >> Share

  65. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:205-213.
    >> Share

  66. MISTRY NA, Sun Z, Sweis J, McCall C, et al
    Development and Validation of a Prostate Biopsy Risk Calculator in Black Men.
    J Urol. 2024;211:223-233.
    >> Share

  67. BECHTEL MD, Michel C, Srinivasan P, Chalise P, et al
    Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression.
    J Urol. 2024 Feb 1:101097JU0000000000003849. doi: 10.1097/JU.0000000000003849.
    >> Share

  68. BERNARDINO R, Sayyid RK, Lajkosz K, Al-Daqqaq Z, et al
    Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through (18)F-DCFPyL?Prostate-Specific Membrane Antigen?Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients.
    J Urol. 2024 Feb 1:101097JU0000000000003850. doi: 10.1097/JU.0000000000003850.
    >> Share

    January 2024
  69. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2024 Jan 15:101097JU0000000000003835. doi: 10.1097/JU.0000000000003835.
    >> Share

  70. GARNICK MB, Hafron J, Crawford ED
    Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2024 Jan 5:101097JU0000000000003831. doi: 10.1097/JU.0000000000003831.
    >> Share

    December 2023
  71. VAN NESTE L, Henao R, Wojno KJ, Signes J, et al
    Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
    J Urol. 2023 Dec 26:101097JU0000000000003824. doi: 10.1097/JU.0000000000003824.
    >> Share

  72. STIRA J, Gravina C, Lombardo R, De Nunzio C, et al
    Letter: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone?Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2023 Dec 22:101097JU0000000000003830. doi: 10.1097/JU.0000000000003830.
    >> Share

  73. REZAEE ME, Pallauf M, Fletcher SA, Han M, et al
    Risk of Biochemical Recurrence in Patients with Grade Group 1 Prostate Cancer with Extraprostatic Extension Treated with Radical Prostatectomy.
    J Urol. 2023 Dec 18:101097JU0000000000003825. doi: 10.1097/JU.0000000000003825.
    >> Share

    November 2023
  74. TOSOIAN JJ, Yu A, Brisbane WG
    Innovation and Progress for Screening and Management of Localized Prostate Cancer-What an Exciting Time.
    J Urol. 2023 Nov 27:101097JU0000000000003797. doi: 10.1097/JU.0000000000003797.
    >> Share

  75. JOYCE DD, Filson CP, Herrel LA
    What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2023 Nov 27:101097JU0000000000003798. doi: 10.1097/JU.0000000000003798.
    >> Share

  76. PAGADALA MS, Ryan S, Carter H, Javier-DesLoges J, et al
    Comparison of Genomic Inflation Estimates in Genome-Wide Association Studies Using Genetically-Identified Ancestry versus Self-Identified Race/Ethnicity in Prostate Cancer Patients in ELLIPSE Cohort.
    J Urol. 2023 Nov 27:101097JU0000000000003794. doi: 10.1097/JU.0000000000003794.
    >> Share

  77. LEPOR H
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Reply.
    J Urol. 2023 Nov 15:101097JU0000000000003782. doi: 10.1097/JU.0000000000003782.
    >> Share

  78. CHEN Y, Liang Z, Yan W
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Letter.
    J Urol. 2023 Nov 14:101097JU0000000000003781. doi: 10.1097/JU.0000000000003781.
    >> Share

  79. SESSINE MS, Radoiu CS, Qi J, Labardee C, et al
    Can MRI Help Inform Which Men with a History of Multifocal High Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer?
    J Urol. 2023 Nov 6:101097JU0000000000003775. doi: 10.1097/JU.0000000000003775.
    >> Share

  80. SINGHAL U, Hollenbeck BK, Kaffenberger SD, Salami SS, et al
    Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice.
    J Urol. 2023;210:771-777.
    >> Share

    October 2023
  81. CRAWFORD ED, Hafron JM, Debruyne F, Wallis C, et al
    Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2023 Oct 5:101097JU0000000000003721. doi: 10.1097/JU.0000000000003721.
    >> Share

  82. TERAMOTO Y, Wang Y, Miyamoto H
    Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?
    J Urol. 2023;210:639-648.
    >> Share

    September 2023
  83. MONTORSI F, Gandaglia G, Salonia A, Briganti A, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003683. doi: 10.1097/JU.0000000000003683.
    >> Share

  84. SHAH N, Ioffe V
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003682. doi: 10.1097/JU.0000000000003682.
    >> Share

    August 2023
  85. TANG W, Tang Y, Qi L, Zhang Y, et al
    BPH-related False Positive of PSMA-PET in the Diagnosis of Prostate Cancer: the Achilles' Heel of Biopsy-free Radical Prostatectomy?
    J Urol. 2023 Aug 30:101097JU0000000000003680. doi: 10.1097/JU.0000000000003680.
    >> Share

  86. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Aug 25:101097JU0000000000003675. doi: 10.1097/JU.0000000000003675.
    >> Share

  87. JOYCE DD, Schulte PJ, Kwon ED, Dusetzina SB, et al
    Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment.
    J Urol. 2023;210:290-298.
    >> Share

  88. URKMEZ A, Davis JW
    Freehand Versus Grid-based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Reply.
    J Urol. 2023;210:249.
    >> Share

  89. OZDEN E, Ozturk E, Turgut AT
    Freehand Versus Grid-based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Letter.
    J Urol. 2023;210:248-249.
    >> Share

  90. BERMAN DM, Lee AY, Lesurf R, Patel PG, et al
    Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance.
    J Urol. 2023;210:257-271.
    >> Share

  91. CHANG K, Greenberg SA, Cowan JE, Parker R, et al
    Stability of Prognostic Estimation Using the CAPRA Score Incorporating Imaging-based vs Physical Exam-based Staging.
    J Urol. 2023;210:281-289.
    >> Share

  92. BRITTON CJ, Sharma V, Fadel AE, Bearrick E, et al
    Vesicourethral Anastomotic Stenosis Following Radical Prostatectomy: Risk Factors, Natural History, and Treatment Outcomes.
    J Urol. 2023;210:312-322.
    >> Share

    July 2023
  93. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Jul 28:101097JU0000000000003633. doi: 10.1097/JU.0000000000003633.
    >> Share

  94. MONTORSI F, Stabile A, Gandaglia G, Briganti A, et al
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Jul 14:101097JU0000000000003614. doi: 10.1097/JU.0000000000003614.
    >> Share


  95. MP44-04 Importance of the Ultrasound Characteristics of Regions of Interest by MRI and the Additional Target Biopsy Around Their Peri-hypoechoic Lesions in MR/TRUS Software Fusion Biopsy to Improve Detection Rate of Prostate Cancer.
    J Urol. 2023;210:223.
    >> Share

    June 2023
  96. YIM K, Ma C, Carlsson S, Lilja H, et al
    Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.
    J Urol. 2023 Jun 29:101097JU0000000000003603. doi: 10.1097/JU.0000000000003603.
    >> Share

  97. JANI AB, Ravizzini GC, Gartrell BA, Siegel BA, et al
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.
    J Urol. 2023 Jun 23:101097JU0000000000003598. doi: 10.1097/JU.0000000000003598.
    >> Share

  98. MAI Z, Zhou Z
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Letter.
    J Urol. 2023 Jun 22:101097JU0000000000003597. doi: 10.1097/JU.0000000000003597.
    >> Share

  99. JOYCE DD, Qin X, Sharma V, Boorjian SA, et al
    The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer.
    J Urol. 2023 Jun 21:101097JU0000000000003592. doi: 10.1097/JU.0000000000003592.
    >> Share

  100. YANAGISAWA T, Rajwa P, Kawada T, Mori K, et al
    Efficacy of Systemic Treatment in Prostate Cancer Patients with Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    J Urol. 2023 Jun 20:101097JU0000000000003594. doi: 10.1097/JU.0000000000003594.
    >> Share

  101. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Jun 19:101097JU0000000000003587. doi: 10.1097/JU.0000000000003587.
    >> Share

  102. WYSOCK JS, Rapoport E, Hernandez H, Gogaj R, et al
    Biopsy Assessment of Oncologic Control Three Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men with Intermediate Risk Prostate Cancer.
    J Urol. 2023 Jun 7:101097JU0000000000003569. doi: 10.1097/JU.0000000000003569.
    >> Share

  103. BRAILLON A
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Jun 1:101097JU0000000000003567. doi: 10.1097/JU.0000000000003567.
    >> Share

    May 2023
  104. SHAH N, Ioffe V
    Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Letter.
    J Urol. 2023 May 30:101097JU0000000000003564. doi: 10.1097/JU.0000000000003564.
    >> Share

  105. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 May 18:101097JU0000000000003541. doi: 10.1097/JU.0000000000003541.
    >> Share

  106. ANDREWS JR, Sood A, Chapin BF
    Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer.
    J Urol. 2023 May 17:101097JU0000000000003495. doi: 10.1097/JU.0000000000003495.
    >> Share

  107. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 May 3:101097JU0000000000003477. doi: 10.1097/JU.0000000000003477.
    >> Share


  108. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol. 2023 May 2:101097JU0000000000003518. doi: 10.1097/JU.0000000000003518.
    >> Share

  109. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023;209:1026-1028.
    >> Share

  110. AVOLIO PP, Polascik TJ, Rastinehad A, de la Rosette J, et al
    Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. Letter.
    J Urol. 2023;209:848-849.
    >> Share

  111. SHAH RB
    Point/Counterpoint: Gleason Score 6/Grade Group 1 Prostate Cancer Should Renamed as "Non-cancer" to Improve Public Health-A Wrong Idea From a Pathologist's Perspective.
    J Urol. 2023 May 1:101097JU0000000000003510. doi: 10.1097/JU.0000000000003510.
    >> Share

  112. ZHOU M, Paner GP
    Grade Group 1 (Gleason Score 6) Prostate Cancer Should be Re-named to Improve Public Health: Pathologists' Perspective.
    J Urol. 2023 May 1:101097JU0000000000003511. doi: 10.1097/JU.0000000000003511.
    >> Share

    April 2023
  113. JANI AB, Ravizzini GC, Gartrell BA, Siegel BA, et al
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 PET in Men with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
    J Urol. 2023 Apr 26:101097JU0000000000003493. doi: 10.1097/JU.0000000000003493.
    >> Share

  114. LOWRANCE W, Dreicer R, Jarrard DF, Scarpato KR, et al
    Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023).
    J Urol. 2023 Apr 25:101097JU0000000000003452. doi: 10.1097/JU.0000000000003452.
    >> Share

  115. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.
    J Urol. 2023 Apr 25:101097JU0000000000003491. doi: 10.1097/JU.0000000000003491.
    >> Share

  116. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.
    J Urol. 2023 Apr 25:101097JU0000000000003492. doi: 10.1097/JU.0000000000003492.
    >> Share

  117. MARTINI A, Wever L, Soeterik TFW, Rakauskas A, et al
    Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma.
    J Urol. 2023 Apr 13:101097JU0000000000003442. doi: 10.1097/JU.0000000000003442.
    >> Share

  118. BARABAN E, Erak E, Fatima A, Akbari A, et al
    Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
    J Urol. 2023 Apr 12:101097JU0000000000003461. doi: 10.1097/JU.0000000000003461.
    >> Share

  119. HO MD, Ross AE, Eggener SE
    Risk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance.
    J Urol. 2023 Apr 12:101097JU0000000000003454. doi: 10.1097/JU.0000000000003454.
    >> Share

  120. SHAH N, Ioffe V
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Apr 11:101097JU0000000000003458. doi: 10.1097/JU.0000000000003458.
    >> Share

  121. KA-FUNG CHIU P, Leow JJ, Chiang CH, Mok A, et al
    Prostate Health Index Density Outperforms PSA Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal MRI Prostates: A Multicenter Evaluation.
    J Urol. 2023 Apr 10:101097JU0000000000003450. doi: 10.1097/JU.0000000000003450.
    >> Share

  122. GUIDOTTI A, Lombardo R, De Nunzio C
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003456. doi: 10.1097/JU.0000000000003456.
    >> Share

  123. HABASHY D, Reddy D, Peters M, Shah TT, et al
    Evaluation of Outcomes following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
    J Urol. 2023 Apr 4:101097JU0000000000003443. doi: 10.1097/JU.0000000000003443.
    >> Share


  124. Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2023;209:815.
    >> Share

    March 2023
  125. BREEN KE, Symecko H, Spielman K, Gebert R, et al
    Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
    J Urol. 2023 Mar 28:101097JU0000000000003186. doi: 10.1097/JU.0000000000003186.
    >> Share

  126. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Mar 23:101097JU0000000000003421. doi: 10.1097/JU.0000000000003421.
    >> Share

  127. JIN S, Wu L, Mai Z, Yan W, et al
    A Multicenter, Randomized, Single-Blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-Intermediate Risk Prostate Cancer. Letter.
    J Urol. 2023 Mar 16:101097JU0000000000003404. doi: 10.1097/JU.0000000000003404.
    >> Share

  128. ZHANG K, Teoh J, Laguna P, Ng CF, et al
    A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. Reply.
    J Urol. 2023 Mar 16:101097JU0000000000003405. doi: 10.1097/JU.0000000000003405.
    >> Share

  129. SCHNEIDER AC, Chandrasekar T, Bowler N, Fogg R, et al
    Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
    J Urol. 2023 Mar 9:101097JU0000000000003396. doi: 10.1097/JU.0000000000003396.
    >> Share

  130. HUSSAIN M, Sternberg CN, Efstathiou E, Fizazi K, et al
    Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
    J Urol. 2023;209:532-539.
    >> Share

    February 2023
  131. SWAMI U, Hong A, El-Chaar NN, Ramaswamy K, et al
    The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer.
    J Urol. 2023 Feb 15:101097JU0000000000003370. doi: 10.1097/JU.0000000000003370.
    >> Share

  132. LEAPMAN MS, Wang R, Loeb S, Seibert TM, et al
    Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
    J Urol. 2023 Feb 8:101097JU0000000000003159. doi: 10.1097/JU.0000000000003159.
    >> Share

  133. PATEL N, Hughes A, Zhang H, Brisbane W, et al
    Utility of MRI for Localizing Prostate Cancer near the Urethra in Men Who are Candidates for Focal Gland Ablation.
    J Urol. 2023 Feb 8:101097JU0000000000003197. doi: 10.1097/JU.0000000000003197.
    >> Share


  134. Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.
    J Urol. 2023;209:450.
    >> Share

  135. SCHWEIZER MT, True L, Gulati R, Zhao Y, et al
    Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
    J Urol. 2023;209:354-363.
    >> Share

    January 2023
  136. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2023 Jan 25:101097JU0000000000003180. doi: 10.1097/JU.0000000000003180.
    >> Share

  137. TOUIJER K, Plata Bello A
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Reply.
    J Urol. 2023 Jan 19:101097JU0000000000003178. doi: 10.1097/JU.0000000000003178.
    >> Share

  138. DE BARROS HA, Berrens AC, Donswijk ML, Wit EMK, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Letter.
    J Urol. 2023 Jan 17:101097JU0000000000003177. doi: 10.1097/JU.0000000000003177.
    >> Share

  139. SAFARINEJAD MR, Safarinejad S, Shafiei N, Safarinejad S, et al
    Expression of Concern: G Protein beta3 Subunit Gene C825T Polymorphism and its Association with the Presence and Clinicopathological Characteristics of Prostate Cancer.
    J Urol. 2023 Jan 10:101097JU0000000000003145. doi: 10.1097/JU.0000000000003145.
    >> Share

  140. CARROLL P
    Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. Reply.
    J Urol. 2023;209:73.
    >> Share

  141. SHOJI S, Kaya T, Tanaka Y, Uemura K, et al
    Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reportin
    J Urol. 2023;209:187-197.
    >> Share

    December 2022
  142. LIN DW
    Point-Counterpoint: Active Surveillance Should Still be Preferred Management for All (or Nearly All) Men with Low Risk Prostate Cancer.
    J Urol. 2022 Dec 27:101097JU0000000000003134. doi: 10.1097/JU.0000000000003134.
    >> Share

  143. TIMILSHINA N, Alibhai SMH, Tomlinson G, Sander B, et al
    Long-Term Outcomes following Active Surveillance of Low-Grade Prostate Cancer: A Population-Based Study Using a Landmark Approach.
    J Urol. 2022 Dec 7:101097JU0000000000003097. doi: 10.1097/JU.0000000000003097.
    >> Share

  144. HIGANO CS, Hafron J
    Adherence With Oral Anticancer Therapies: Clinical Trial versus Real-World Experiences with a Focus on Prostate Cancer.
    J Urol. 2022 Dec 6:101097JU0000000000003081. doi: 10.1097/JU.0000000000003081.
    >> Share

  145. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022;208:1349-1351.
    >> Share

  146. ANDREWS JR, Ahmed ME, Sharma V, Britton C, et al
    Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.
    J Urol. 2022;208:1240-1249.
    >> Share

  147. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Dec 1:101097JU0000000000003088. doi: 10.1097/JU.0000000000003088.
    >> Share

  148. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.
    J Urol. 2022 Dec 1:101097JU0000000000003080. doi: 10.1097/JU.0000000000003080.
    >> Share

    November 2022
  149. DE LA ROSETTE J, Dominguez-Escrig J, Zhang K, Teoh J, et al
    A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
    J Urol. 2022 Nov 28:101097JU0000000000003051. doi: 10.1097/JU.0000000000003051.
    >> Share

  150. PITTMAN A, Moses KA, Washington SL 3rd
    Urologists in Advocacy: The Key to Addressing Disparities in Prostate Cancer.
    J Urol. 2022 Nov 17:101097JU0000000000003000. doi: 10.1097/JU.0000000000003000.
    >> Share

  151. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Nov 16:101097JU0000000000003046. doi: 10.1097/JU.0000000000003046.
    >> Share

  152. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2022 Nov 14:101097JU0000000000003049. doi: 10.1097/JU.0000000000003049.
    >> Share

  153. MARTINI A, Valerio M
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Reply.
    J Urol. 2022 Nov 11:101097JU0000000000003055. doi: 10.1097/JU.0000000000003055.
    >> Share

  154. BOWER PE
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Letter.
    J Urol. 2022 Nov 11:101097JU0000000000003054. doi: 10.1097/JU.0000000000003054.
    >> Share

  155. LANNES F, Baboudjian M, Ruffion A, Rouy M, et al
    Radioisotope-Guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients with Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).
    J Urol. 2022 Nov 4:101097JU0000000000003043. doi: 10.1097/JU.0000000000003043.
    >> Share

  156. OZMAN O, Tillier CN, van Muilekom E, van de Poll-Franse LV, et al
    Financial Toxicity After Robot-Assisted Radical Prostatectomy and Its Relation with Oncologic, Functional Outcomes.
    J Urol. 2022;208:978-986.
    >> Share

  157. DOAN P, Scheltema MJ, Amin A, Shnier R, et al
    Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial.
    J Urol. 2022;208:1028-1036.
    >> Share

  158. MAZZONE E, Gandaglia G, Stabile A, Bravi CA, et al
    Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy.
    J Urol. 2022;208:1046-1055.
    >> Share

  159. FILSON CP, Zhu K, Huang Y, Zheng Y, et al
    Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
    J Urol. 2022;208:1037-1045.
    >> Share

    October 2022
  160. PAUDEL R, Madan R, Qi J, Ferrante S, et al
    The Use and Short-term Outcomes of Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer Managed With Active Surveillance: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
    J Urol. 2022 Oct 13:101097JU0000000000003012. doi: 10.1097/JU.0000000000003012.
    >> Share

  161. HANSEN NF, Linscott JA, Hayn MH, Ryan ST, et al
    PSA testing behaviors for prostate cancer screening among U.S. immigrants: a cross-sectional analysis using the NHIS.
    J Urol. 2022 Oct 11:101097JU0000000000002993. doi: 10.1097/JU.0000000000002993.
    >> Share

  162. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Oct 10:101097JU0000000000003008. doi: 10.1097/JU.0000000000003008.
    >> Share

  163. BABOUDJIAN M, Ploussard G
    Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort. Letter.
    J Urol. 2022 Oct 10:101097JU0000000000002991. doi: 10.1097/JU.0000000000002991.
    >> Share

  164. ZATTONI F, Marra G, Kasivisvanathan V, Grummet J, et al
    The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi
    J Urol. 2022;208:830-837.
    >> Share

  165. RAVI P, Kwak L, Xie W, Kelleher K, et al
    Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
    J Urol. 2022;208:838-845.
    >> Share

  166. OAKE JD, Shiff B, Harasemiw O, Tangri N, et al
    The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Nonmetastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
    J Urol. 2022;208:846-854.
    >> Share

    September 2022
  167. LABBATE CV, Klotz L, Morrow M, Cooperberg M, et al
    Focal Therapy for Prostate Cancer -Evolutionary Parallels to Breast Cancer Treatment.
    J Urol. 2022 Sep 21:101097JU0000000000002972. doi: 10.1097/JU.0000000000002972.
    >> Share

  168. ROULEAU M, Neveu B, Caron P, Morin F, et al
    Extensive Alteration of Androgen Precursor Levels after Castration in Prostate Cancer Patients and Their Association with Active Androgen Level.
    J Urol. 2022 Sep 14:101097JU0000000000002923. doi: 10.1097/JU.0000000000002923.
    >> Share

  169. JOYCE DD, Sharma V, Jiang DH, Van Houten HK, et al
    Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
    J Urol. 2022 Sep 12:101097JU0000000000002856. doi: 10.1097/JU.0000000000002856.
    >> Share

  170. LOPEZ BM, Boville GA, Bernardos GB, Marckert XA, et al
    Focal Therapy of Prostate Cancer Index Lesion with Irreversible Electroporation. A Prospective Study with a Median Follow-Up of Three Years.
    J Urol. 2022 Sep 8:101097JU0000000000002970. doi: 10.1097/JU.0000000000002970.
    >> Share

  171. DE LA CALLE CM, Mamawala MM, Landis P, Macura KJ, et al
    Clinical Significance of Perineural Invasion in Men with Grade Group 1 Prostate Cancer on Active Surveillance.
    J Urol. 2022 Sep 8:101097JU0000000000002963. doi: 10.1097/JU.0000000000002963.
    >> Share

  172. SHEE K, Washington SL 3rd, Cowan JE, de la Calle CM, et al
    Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort.
    J Urol. 2022 Sep 6:101097JU0000000000002956. doi: 10.1097/JU.0000000000002956.
    >> Share

  173. SHIRK JD, Reiter R, Wallen EM, Pak R, et al
    Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial.
    J Urol. 2022;208:618-625.
    >> Share

    August 2022
  174. DE B, Pasalic D, Barocas DA, Wallis CJD, et al
    Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study.
    J Urol. 2022 Aug 25:101097JU0000000000002902. doi: 10.1097/JU.0000000000002902.
    >> Share

  175. TROCK BJ, Jing Y, Mabey B, Sangale Z, et al
    Cell Cycle Progression Score, But Not PTEN Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-Risk Prostate Cancer in Men Treated with and without Salvage Radiotherapy.
    J Urol. 2022 Aug 25:101097JU0000000000002922. doi: 10.1097/JU.0000000000002922.
    >> Share

  176. KIM IE JR, Pareek G
    The Key to Addressing Disparities in Prostate Cancer: Urologists in Advocacy?
    J Urol. 2022 Aug 24:101097JU0000000000002930. doi: 10.1097/JU.0000000000002930.
    >> Share

  177. RACHUBINSKI P, Witt JH, Budaus L, Zinke J, et al
    Precision-Guidance vs. Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious mpMRI Lesions.
    J Urol. 2022 Aug 24:101097JU0000000000002921. doi: 10.1097/JU.0000000000002921.
    >> Share

  178. GABRIELSON AT, Choi U, Fletcher SA, Pavlovich CP, et al
    Lost in Transparency: The 21st Century Cures Act ("Open Notes") and Prostate Cancer Care.
    J Urol. 2022 Aug 19:101097JU0000000000002924. doi: 10.1097/JU.0000000000002924.
    >> Share

  179. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Aug 19:101097JU0000000000002909. doi: 10.1097/JU.0000000000002909.
    >> Share

  180. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Aug 16:101097JU0000000000002870. doi: 10.1097/JU.0000000000002870.
    >> Share

  181. ABUSAMRA SM, Solorzano MA, Luke M, Quarles J, et al
    Satisfaction with Clinician-Led Germline Genetic Counseling in Patients with Prostate Cancer.
    J Urol. 2022 Aug 5:101097JU0000000000002865. doi: 10.1097/JU.0000000000002865.
    >> Share

  182. GLOGER S, Ubrig B, Boy A, Leyh-Bannurah SR, et al
    Bilateral Peritoneal Flaps Reduce Incidence and Complications of Lymphoceles after Robotic Radical Prostatectomy with Pelvic Lymph Node Dissection-Results of the Prospective Randomized Multicenter Trial ProLy.
    J Urol. 2022;208:333-340.
    >> Share

  183. GOODE PS, Johnson TM 2nd, Newman DK, Vaughan CP, et al
    Perioperative Mobile Telehealth Program for Post-Prostatectomy Incontinence: A Randomized Clinical Trial.
    J Urol. 2022;208:379-387.
    >> Share

  184. ABOU ZEINAB M, Beksac AT, Corse T, Talamini S, et al
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management.
    J Urol. 2022;208:369-378.
    >> Share

    July 2022
  185. BRANT A, Lewicki P, Wu X, Sze C, et al
    Impact of Left-digit Age Bias in the Treatment of Localized Prostate Cancer.
    J Urol. 2022 Jul 28:101097JU0000000000002857. doi: 10.1097/JU.0000000000002857.
    >> Share

  186. EASTHAM JA, Boorjian SA, Kirkby E
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.
    J Urol. 2022 Jul 5:101097JU0000000000002854. doi: 10.1097/JU.0000000000002854.
    >> Share

  187. WESTHOFEN T, Buchner A, Kasivisvanathan V, Lennartz S, et al
    The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy.
    J Urol. 2022 Jul 5:101097JU0000000000002826. doi: 10.1097/JU.0000000000002826.
    >> Share

  188. FAN S, Zhang Z, Wang J, Xiong S, et al
    Robot-Assisted Radical Prostatectomy Using the KangDuo Surgical Robot-01 System: A Prospective, Single-Center, Single-Arm Clinical Study.
    J Urol. 2022;208:119-127.
    >> Share

  189. TOPS SCM, Grootenhuis JGA, Derksen AM, Giardina F, et al
    The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications.
    J Urol. 2022;208:109-118.
    >> Share

    June 2022
  190. STINESEN KOLLBERG K, Holmberg E, Josefsson A, Hugosson J, et al
    Prostate-specific antigen (PSA) and biopsy contamination in the Goteborg-1 randomized, population-based, prostate cancer screening trial.
    J Urol. 2022 Jun 30:101097JU0000000000002835. doi: 10.1097/JU.0000000000002835.
    >> Share

  191. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Jun 27:101097JU0000000000002796. doi: 10.1097/JU.0000000000002796.
    >> Share

  192. XUE X, Yang X, Ji Z, Xie Y, et al
    Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men. Letter.
    J Urol. 2022 Jun 21:101097JU0000000000002830. doi: 10.1097/JU.0000000000002830.
    >> Share

  193. ABOU ZEINAB M, Kaouk J
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Reply.
    J Urol. 2022 Jun 3:101097JU0000000000002785. doi: 10.1097/JU.0000000000002785.
    >> Share

  194. TIAN Y, Zhang H, Luo G
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Letter.
    J Urol. 2022 Jun 3:101097JU0000000000002784. doi: 10.1097/JU.0000000000002784.
    >> Share

  195. TURCHAN WT, Cutright D, Wu T, Leng JX, et al
    Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.
    J Urol. 2022;207:1236-1245.
    >> Share

    May 2022
  196. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 May 20:101097JU0000000000002745. doi: 10.1097/JU.0000000000002745.
    >> Share

  197. STEPHENSON AJ, Vourganti S
    Pro: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
    J Urol. 2022 May 12:101097JU0000000000002776. doi: 10.1097/JU.0000000000002776.
    >> Share

  198. SIDDIQUI MM
    Con: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
    J Urol. 2022 May 12:101097JU0000000000002777. doi: 10.1097/JU.0000000000002777.
    >> Share

  199. COLE AP, Chen X, Langbein BJ, Giganti F, et al
    Geographic Variability, Time Trends and Association of Preoperative MRI with Surgical Outcomes for Elderly US Men with Prostate Cancer: A SEER-Medicare Analysis.
    J Urol. 2022 May 10:101097JU0000000000002736. doi: 10.1097/JU.0000000000002736.
    >> Share

  200. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery and Follow-up.
    J Urol. 2022 May 10:101097JU0000000000002758. doi: 10.1097/JU.0000000000002758.
    >> Share

  201. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging and Risk-Based Management.
    J Urol. 2022 May 10:101097JU0000000000002757. doi: 10.1097/JU.0000000000002757.
    >> Share

  202. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.
    J Urol. 2022 May 10:101097JU0000000000002759. doi: 10.1097/JU.0000000000002759.
    >> Share

  203. ZHANG Y, Song M, Mucci LA, Giovannucci EL, et al
    Regular, Long-Duration Multivitamin Use and Risk of Overall and Aggressive Prostate Cancer in the Health Professionals Follow-Up Study.
    J Urol. 2022 May 6:101097JU0000000000002735. doi: 10.1097/JU.0000000000002735.
    >> Share

  204. RADHAKRISHNAN A, Wallner LP, Skolarus TA, George AK, et al
    Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.
    J Urol. 2022 May 6:101097JU0000000000002734. doi: 10.1097/JU.0000000000002734.
    >> Share


  205. Findings in 1,123 Men with Preoperative (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Im
    J Urol. 2022;207:1166.
    >> Share

  206. GONDOPUTRO W, Thompson J, Evans M, Bolton D, et al
    How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires.
    J Urol. 2022;207:1048-1056.
    >> Share

    April 2022
  207. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Apr 25:101097JU0000000000002705. doi: 10.1097/JU.0000000000002705.
    >> Share

  208. FRANLUND M, Mansson M, Godtman RA, Aus G, et al
    Results from 22 years of Follow-Up in the Goteborg Randomized Population-Based Prostate Cancer Screening Trial.
    J Urol. 2022 Apr 15:101097JU0000000000002696. doi: 10.1097/JU.0000000000002696.
    >> Share

  209. LEWICKI P, Brant A, Shoag JE
    Re: A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
    J Urol. 2022 Apr 8:101097JU0000000000002700. doi: 10.1097/JU.0000000000002700.
    >> Share

  210. NYAME YA, Schraidt JA, Chakoian M, Nissenberg MG, et al
    A Patient-Centered Approach to Research Prioritization in Prostate Cancer.
    J Urol. 2022 Apr 8:101097JU0000000000002694. doi: 10.1097/JU.0000000000002694.
    >> Share

  211. JIBARA GA, Perera M, Vertosick EA, Sjoberg DD, et al
    Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance.
    J Urol. 2022 Apr 4:101097JU0000000000002668. doi: 10.1097/JU.0000000000002668.
    >> Share

  212. DASKIVICH TJ, Gale R, Luu M, Naser-Tavakolian A, et al
    Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations.
    J Urol. 2022 Apr 4:101097JU0000000000002675. doi: 10.1097/JU.0000000000002675.
    >> Share

  213. PERERA M, Assel MJ, Benfante NE, Vickers AJ, et al
    Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
    J Urol. 2022 Apr 1:101097JU0000000000002685. doi: 10.1097/JU.0000000000002685.
    >> Share

    March 2022
  214. MONTORSI F, Mazzone E, Gandaglia G, Stabile A, et al
    Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
    J Urol. 2022 Mar 29:101097JU0000000000002680. doi: 10.1097/JU.0000000000002680.
    >> Share

  215. CHIERIGO F, Borghesi M, Mantica G, Terrone C, et al
    Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Reply.
    J Urol. 2022 Mar 29:101097JU0000000000002681. doi: 10.1097/JU.0000000000002681.
    >> Share

  216. DURSUN F, Wang CP, MacCarthy D, Mansour AM, et al
    Absolute PSA after 6 Months of Androgen Deprivation Therapy is a Predictor of Overall and Cancer Specific Mortality in Men with Hormone-Sensitive Prostate Cancer.
    J Urol. 2022 Mar 28:101097JU0000000000002676. doi: 10.1097/JU.0000000000002676.
    >> Share

  217. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Mar 17:101097JU0000000000002511. doi: 10.1097/JU.0000000000002511.
    >> Share

  218. BRIGHT JR, Lis RT, Ku AT, Terrigino NT, et al
    PROSTATE-SPECIFIC Membrane Antigen Is a Biomarker for Residual Disease Following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.
    J Urol. 2022 Mar 1:101097JU0000000000002492. doi: 10.1097/JU.0000000000002492.
    >> Share

  219. KAN KM, Tin AL, Stearns GL, Eastham JA, et al
    De Novo Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors.
    J Urol. 2022;207:601-608.
    >> Share

  220. BAHOUTH Z, Laniado M, Fowler R, Charlesworth PJS, et al
    Positive Surgical Margins Rate of Retzius-Sparing Robot-Assisted Radical Prostatectomy in a Contemporary, Unselected Cohort.
    J Urol. 2022;207:609-616.
    >> Share

    February 2022
  221. KAWA SM, Stroomberg HV, Larsen SB, Helgstrand JT, et al
    A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
    J Urol. 2022 Feb 25:101097JU0000000000002491. doi: 10.1097/JU.0000000000002491.
    >> Share

  222. MAGNANI CJ, Hernandez-Boussard T, Baker LC, Goldhaber-Fiebert JD, et al
    Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
    J Urol. 2022 Feb 25:101097JU0000000000002490. doi: 10.1097/JU.0000000000002490.
    >> Share

  223. KANG DW, Fairey AS, Boule NG, Field CJ, et al
    A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance.
    J Urol. 2022 Feb 17:101097JU0000000000002334. doi: 10.1097/JU.0000000000002334.
    >> Share

  224. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Feb 16:101097JU0000000000002477. doi: 10.1097/JU.0000000000002477.
    >> Share

  225. LOEB S, Borno HT, Gomez S, Ravenell J, et al
    Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men.
    J Urol. 2022 Feb 4:101097JU0000000000002257. doi: 10.1097/JU.0000000000002257.
    >> Share

  226. KACHANOV M, Leyh-Bannurah SR, Roberts MJ, Sauer M, et al
    Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
    J Urol. 2022;207:333-340.
    >> Share

  227. OTLES E, Denton BT, Qu B, Murali A, et al
    Development and Validation of Models to Predict Pathological Outcomes of Radical Prostatectomy in Regional and National Cohorts.
    J Urol. 2022;207:358-366.
    >> Share

  228. CLEMENTS MB, Tin AL, Estes CL, Jibara G, et al
    Characterization of Symptoms after Radical Prostatectomy and Their Relation to Postoperative Complications.
    J Urol. 2022;207:367-374.
    >> Share

    January 2022
  229. ANDRUSKA N, Fischer-Valuck BW, Waters M, Diaz EJ, et al
    Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-only versus Whole Pelvic Radiation Therapy.
    J Urol. 2022 Jan 27:101097JU0000000000002455. doi: 10.1097/JU.0000000000002455.
    >> Share

  230. KUPPERMANN D, Calais J, Marks LS
    Imaging Prostate Cancer: Clinical Utility of Prostate-specific Membrane Antigen (PSMA).
    J Urol. 2022 Jan 27:101097JU0000000000002457. doi: 10.1097/JU.0000000000002457.
    >> Share

  231. SCHIFF H
    Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. Letter.
    J Urol. 2022 Jan 26:101097JU0000000000002456. doi: 10.1097/JU.0000000000002456.
    >> Share

  232. ROSENBERG JE, Jarosek S, Spilseth B, Huang YH, et al
    Diagnosing Prostate Cancer: The Role of Intravesicular Prostatic Gland Protrusion on Accuracy of Prostate Biopsies.
    J Urol. 2022 Jan 26:101097JU0000000000002448. doi: 10.1097/JU.0000000000002448.
    >> Share

  233. EGGENER S, Siemens DR
    Prostate Cancer, Decisional Regret and Exercise.
    J Urol. 2022 Jan 26:101097JU0000000000002453. doi: 10.1097/JU.0000000000002453.
    >> Share

  234. WANG M, Semerjian A, Lane BR, George AK, et al
    Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Letter.
    J Urol. 2022 Jan 20:101097JU0000000000002442. doi: 10.1097/JU.0000000000002442.
    >> Share

  235. PLATA BELLO A, Apatov SE, Benfante NE, Rivero Belenchon I, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node.
    J Urol. 2022 Jan 20:101097JU0000000000002439. doi: 10.1097/JU.0000000000002439.
    >> Share

  236. SHAHAIT M, Cheaib JG, Davicioni E, Liu Y, et al
    Does Perioperative Testosterone Predict Post-prostatectomy Genomic Risk Score?
    J Urol. 2022 Jan 20:101097JU0000000000002440. doi: 10.1097/JU.0000000000002440.
    >> Share

  237. PAN A, Reingold RE, Zhao JL, Moy A, et al
    Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
    J Urol. 2022 Jan 12:101097JU0000000000002425. doi: 10.1097/JU.0000000000002425.
    >> Share

  238. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Jan 7:101097JU0000000000002413. doi: 10.1097/JU.0000000000002413.
    >> Share

  239. TANAKA T, Kawashima A, Rangel LJ, Schulte PJ, et al
    Long Term Risk of Clinical Progression Utilizing MRI Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence Following Radical Prostatectomy.
    J Urol. 2022 Jan 4:101097JU0000000000002421. doi: 10.1097/JU.0000000000002421.
    >> Share

  240. NAYAK JG
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis. Reply.
    J Urol. 2022 Jan 4:101097JU0000000000002419. doi: 10.1097/JU.0000000000002419.
    >> Share

  241. GROSSO AA, Di Maida F, Mari A, Minervini A, et al
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis. Letter.
    J Urol. 2022 Jan 4:101097JU0000000000002418. doi: 10.1097/JU.0000000000002418.
    >> Share

  242. CHAPPIDI MR, Bell A, Cowan JE, Greenberg SA, et al
    The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
    J Urol. 2022 Jan 4:101097JU0000000000002420. doi: 10.1097/JU.0000000000002420.
    >> Share

  243. LUCKENBAUGH AN, Wallis CJD, Huang LC, Wittmann D, et al
    Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.
    J Urol. 2022 Jan 3:101097JU0000000000002370. doi: 10.1097/JU.0000000000002370.
    >> Share

  244. PINTHUS JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, et al
    Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naive Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy.
    J Urol. 2022 Jan 3:101097JU0000000000002384. doi: 10.1097/JU.0000000000002384.
    >> Share

  245. LEE A, Chen K, Tay KJ
    Can We Avoid a Systematic Biopsy in Men with PI-RADS((R)) 5? Letter.
    J Urol. 2022;207:240-241.
    >> Share

  246. TAFURI A, Iwata A, Shakir A, Iwata T, et al
    Can We Avoid a Systematic Biopsy in Men with PI-RADS(R) 5? Reply.
    J Urol. 2022;207:241-242.
    >> Share

  247. CORKUM MT, Loblaw DA, Morton G, Louie AV, et al
    Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities.
    J Urol. 2022;207:118-126.
    >> Share

  248. CHANG P, Wagner AA, Regan MM, Smith JA, et al
    Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
    J Urol. 2022;207:127-136.
    >> Share

  249. WILLIAMS C, Ahdoot M, Daneshvar MA, Hague C, et al
    Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
    J Urol. 2022;207:95-107.
    >> Share

  250. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
    Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    J Urol. 2022;207:108-117.
    >> Share

    December 2021
  251. WASHINGTON SL 3RD, Gore JL, Nyame YA
    Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer.
    J Urol. 2021 Dec 30:101097JU0000000000002417. doi: 10.1097/JU.0000000000002417.
    >> Share

  252. ALKHATIB K, Labban M, Briggs L, Nguyen DD, et al
    Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate-specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
    J Urol. 2021 Dec 30:101097JU0000000000002379. doi: 10.1097/JU.0000000000002379.
    >> Share

  253. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Dec 17:101097JU0000000000002377. doi: 10.1097/JU.0000000000002377.
    >> Share

  254. KAN WC, Hsieh KL, Chen YC, Ho CH, et al
    Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients With Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002340. doi: 10.1097/JU.0000000000002340.
    >> Share

  255. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
    Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002335. doi: 10.1097/JU.0000000000002335.
    >> Share

  256. KINNAIRD A, Yerram NK, O'Connor L, Brisbane W, et al
    MRI-guided Biopsy in Active Surveillance of Prostate Cancer.
    J Urol. 2021 Dec 2:101097JU0000000000002343. doi: 10.1097/JU.0000000000002343.
    >> Share

  257. WAISMAN MALARET AJ, Chang P, Zhu K, Zheng Y, et al
    Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort.
    J Urol. 2021 Dec 2:101097JU0000000000002354. doi: 10.1097/JU.0000000000002354.
    >> Share

  258. SHANKAR PR, Ellimoottil C, George AK, Hadj-Moussa M, et al
    Testing-Related Health Impact of Transrectal and Transperineal Prostate Biopsy as Assessed by Health Utilities.
    J Urol. 2021;206:1403-1410.
    >> Share

    November 2021
  259. CHEN K, Murphy D, Lawrentschuk N
    Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones.
    J Urol. 2021 Nov 17:101097JU0000000000002348. doi: 10.1097/JU.0000000000002348.
    >> Share

  260. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Nov 17:101097JU0000000000002326. doi: 10.1097/JU.0000000000002326.
    >> Share

  261. COOPERBERG MR, Lin DW, Morgan TM, Chapin BF, et al
    Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
    J Urol. 2021 Nov 15:101097JU0000000000002341. doi: 10.1097/JU.0000000000002341.
    >> Share

  262. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
    Timing of Radiotherapy after Radical Prostatectomy: Effects on Health-Related Quality of Life.
    J Urol. 2021;206:1192-1203.
    >> Share

  263. KOWALCZYK KJ, Madi RH, Eden CG, Sooriakumaran P, et al
    Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series.
    J Urol. 2021;206:1184-1191.
    >> Share

    October 2021
  264. LEE MC, Erickson TR, Stock S, Howard LE, et al
    Association Between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes Among Patients with Intermediate- and High-Risk Localized Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002304. doi: 10.1097/JU.0000000000002304.
    >> Share

  265. LOZANO-LORCA M, Olmedo-Requena R, Rodriguez-Barranco M, Redondo-Sanchez D, et al
    Salivary Melatonin Rhythm and Prostate Cancer: CAPLIFE Study.
    J Urol. 2021 Oct 25:101097JU0000000000002294. doi: 10.1097/JU.0000000000002294.
    >> Share

  266. DASKIVICH TJ, Luu M, Freedland SJ, Sandler H, et al
    Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002256. doi: 10.1097/JU.0000000000002256.
    >> Share

  267. YU W, Guo J
    Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
    J Urol. 2021 Oct 25:101097JU0000000000002302. doi: 10.1097/JU.0000000000002302.
    >> Share

  268. RAVEENTHIRAN S, Yaxley WJ, Franklin T, Coughlin G, et al
    Findings in 1123 Men with Pre-operative (68)Ga-PSMA PET/CT and mpMRI Compared to Totally Embedded Radical Prostatectomy Histopathology. Implications for the Diagnosis and Management of Prostate Cancer.
    J Urol. 2021 Oct 25:101097JU0000000000002293. doi: 10.1097/JU.0000000000002293.
    >> Share


  269. Urological Oncology: Prostate Cancer.
    J Urol. 2021 Oct 18:101097JU0000000000002285. doi: 10.1097/JU.0000000000002285.
    >> Share

  270. KAPLAN-MARANS E
    Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Letter.J Urol; 206: 613.
    J Urol. 2021 Oct 11:101097JU0000000000002288. doi: 10.1097/JU.0000000000002288.
    >> Share

  271. ZHANG KW, Guha A
    Response to "Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS): Letter."
    J Urol. 2021 Oct 11:101097JU0000000000002289. doi: 10.1097/JU.0000000000002289.
    >> Share

  272. URKMEZ A, Demirel C, Altok M, Bathala TK, et al
    Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications.
    J Urol. 2021;206:894-902.
    >> Share

  273. BHAT KRS, Covas Moschovas M, Sandri M, Dell'Oglio P, et al
    A Predictive Preoperative and Postoperative Nomogram for Postoperative Potency Recovery after Robot-Assisted Radical Prostatectomy.
    J Urol. 2021;206:942-951.
    >> Share

    September 2021
  274. CHIERIGO F, Wenzel M, Wurnschimmel C, Flammia RS, et al
    Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
    J Urol. 2021 Sep 24:101097JU0000000000002250. doi: 10.1097/JU.0000000000002250.
    >> Share

  275. LEAPMAN MS, Stone K, Wadia R, Park LS, et al
    Prostate Cancer Screening and Incidence Among Aging Persons Living with HIV.
    J Urol. 2021 Sep 24:101097JU0000000000002249. doi: 10.1097/JU.0000000000002249.
    >> Share

  276. MARTINI A, Soeterik TFW, Haverdings H, Rahota RG, et al
    An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
    J Urol. 2021 Sep 22:101097JU0000000000002205. doi: 10.1097/JU.0000000000002205.
    >> Share

  277. XUE AL, Kalapara AA, Ballok ZE, Levy SM, et al
    (68)Ga-PSMA PET SUVmax as a Predictor of Gleason Pattern 4 and Pathologic Upgrading in Intermediate Risk Prostate Cancer.
    J Urol. 2021 Sep 21:101097JU0000000000002254. doi: 10.1097/JU.0000000000002254.
    >> Share

  278. KRAMER JJ, Gu L, Moreira D, Andriole G, et al
    Statin Use and Lower Urinary Tract Symptoms (LUTS) Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
    J Urol. 2021 Sep 21:101097JU0000000000002199. doi: 10.1097/JU.0000000000002199.
    >> Share

  279. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
    Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter.
    J Urol. 2021 Sep 16:101097JU0000000000002245. doi: 10.1097/JU.0000000000002245.
    >> Share

  280. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Sep 9:101097JU0000000000002226. doi: 10.1097/JU.0000000000002226.
    >> Share

  281. GREENBERG SA, Washington SL 3rd, Lonergan PE, Cowan JE, et al
    Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
    J Urol. 2021;206:706-714.
    >> Share

  282. EHDAIE B, Jibara G, Sjoberg DD, Laudone V, et al
    The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial.
    J Urol. 2021;206:662-668.
    >> Share

  283. HINES L, Zhu D, DeMasi M, Babar M, et al
    A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS(R) Score and Ethnicity in a Diverse, Multiethnic Population.
    J Urol. 2021;206:586-594.
    >> Share

  284. SOERENSEN SJC, Fan RE, Seetharaman A, Chen L, et al
    Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy.
    J Urol. 2021;206:604-612.
    >> Share

    August 2021
  285. KIM M, Wu S, Lin SX, Crotty RK, et al
    Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy Combined with Standard Template Improves Prostate Cancer Detection.
    J Urol. 2021 Aug 25:101097JU0000000000002168. doi: 10.1097/JU.0000000000002168.
    >> Share

  286. TIMILSHINA N, Komisarenko M, Martin LJ, Cheung DC, et al
    Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study.
    J Urol. 2021 Aug 20:101097JU0000000000001903. doi: 10.1097/JU.0000000000001903.
    >> Share

  287. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Aug 18:101097JU0000000000002174. doi: 10.1097/JU.0000000000002174.
    >> Share

  288. COOLEY LF, Emeka AA, Meyers TJ, Cooper PR, et al
    Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
    J Urol. 2021 Aug 16:101097JU0000000000001937. doi: 10.1097/JU.0000000000001937.
    >> Share

  289. KHEDIME S, Gelet A, Rouviere O, Lafon C, et al
    Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
    J Urol. 2021;206:325-337.
    >> Share

  290. TAFURI A, Iwata A, Shakir A, Iwata T, et al
    Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS 5 and Prostate Specific Antigen Density Greater than 15.
    J Urol. 2021;206:289-297.
    >> Share

  291. KUMAR RM, Fergusson DA, Lavallee LT, Cagiannos I, et al
    Performance Feedback May Not Improve Radical Prostatectomy Outcomes: The Surgical Report Card (SuRep) Study.
    J Urol. 2021;206:346-353.
    >> Share

    July 2021
  292. RYAN CJ, Ke X, Lafeuille MH, Romdhani H, et al
    Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
    J Urol. 2021 Jul 23:101097JU0000000000002121. doi: 10.1097/JU.0000000000002121.
    >> Share

  293. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Jul 20:101097JU0000000000002132. doi: 10.1097/JU.0000000000002132.
    >> Share

  294. FREEDLAND SJ, Howard LE, Ngo A, Ramirez-Torres A, et al
    Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
    J Urol. 2021 Jul 14:101097JU0000000000002112. doi: 10.1097/JU.0000000000002112.
    >> Share

  295. ROMPRE-BRODEUR A, Marcq G, Tholomier C, Fugaru I, et al
    Role of Systematic Control Biopsies Following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
    J Urol. 2021 Jul 12:101097JU0000000000001934. doi: 10.1097/JU.0000000000001934.
    >> Share

  296. PURYSKO AS, Bullen J, Valdez R, Auschof E, et al
    Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection With MRI: A Matched Cohort Study.
    J Urol. 2021 Jul 6:101097JU0000000000001932. doi: 10.1097/JU.0000000000001932.
    >> Share

    June 2021
  297. TREMBLAY S, Summers-Trasiewicz L, Pouliot F, Crook JM, et al
    Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
    J Urol. 2021 Jun 29:101097JU0000000000001946. doi: 10.1097/JU.0000000000001946.
    >> Share

  298. OAKE JD, Harasemiw O, Tangri N, Ferguson TW, et al
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis.
    J Urol. 2021 Jun 28:101097JU0000000000001942. doi: 10.1097/JU.0000000000001942.
    >> Share

  299. WILLIAMS C, Khondakar NR, Daneshvar MA, O'Connor LP, et al
    The Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by Combined MRI-Fusion and Systematic Biopsy.
    J Urol. 2021 Jun 28:101097JU0000000000001941. doi: 10.1097/JU.0000000000001941.
    >> Share

  300. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Jun 21:101097JU0000000000001921. doi: 10.1097/JU.0000000000001921.
    >> Share

  301. INABA H, Kimura T, Onuma H, Kido M, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men. Reply.
    J Urol. 2021;205:1841-1842.
    >> Share

  302. VAN KALMTHOUT L, Braat A, de Keizer B, Lam M, et al
    Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.
    J Urol. 2021;205:1839-1840.
    >> Share

  303. AMIEL T, Wurnschimmel C, Heck M, Horn T, et al
    Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Obs
    J Urol. 2021;205:1663-1670.
    >> Share

  304. DALY WC, Linscott JA, Han PKJ, Hayn MH, et al
    National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans.
    J Urol. 2021;205:1641-1647.
    >> Share

  305. PATEL HD, Schwen ZR, Campbell JD, Gorin MA, et al
    Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial.
    J Urol. 2021;205:1681-1688.
    >> Share

    May 2021
  306. AGARWAL N, McQuarrie K, Bjartell A, Chowdhury S, et al
    Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
    J Urol. 2021 May 27:101097JU0000000000001841. doi: 10.1097/JU.0000000000001841.
    >> Share

  307. LIFSHITZ K, Ber Y, Shenhar C, Nillson J, et al
    Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.
    J Urol. 2021 May 25:101097JU0000000000001879. doi: 10.1097/JU.0000000000001879.
    >> Share

  308. CHEUNG DC, Alibhai SMH, Martin LJ, Komisarenko M, et al
    Real World Practice Patterns and Predictors of Continuous versus Intermittent ADT Use for Prostate Cancer in Older Men.
    J Urol. 2021 May 25:101097JU0000000000001876. doi: 10.1097/JU.0000000000001876.
    >> Share

  309. MARSHALL CH, Chen Y, Kuo C, Cullen J, et al
    Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
    J Urol. 2021 May 18:101097JU0000000000001797. doi: 10.1097/JU.0000000000001797.
    >> Share

  310. MACDONALD S, Matos A, Wambier C
    Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. Letter.
    J Urol. 2021 May 17:101097JU0000000000001883. doi: 10.1097/JU.0000000000001883.
    >> Share

  311. KLEIN EA
    Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.
    J Urol. 2021 May 17:101097JU0000000000001884. doi: 10.1097/JU.0000000000001884.
    >> Share

  312. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 May 17:101097JU0000000000001865. doi: 10.1097/JU.0000000000001865.
    >> Share

  313. SHAH N, Ioffe V
    Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role? Letter.
    J Urol. 2021 May 13:101097JU0000000000001880. doi: 10.1097/JU.0000000000001880.
    >> Share

  314. MENG X, Chao B, Chen F, Huang R, et al
    Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Reply.
    J Urol. 2021;205:1528-1529.
    >> Share

  315. STAVRINIDES V, Giganti F, Allen C, Kirkham A, et al
    Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.J Urol 2021; 205: 748.
    J Urol. 2021;205:1526-1528.
    >> Share

  316. PUNNEN S, Stoyanova R, Kwon D, Reis IM, et al
    Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.
    J Urol. 2021;205:1344-1351.
    >> Share

  317. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    >> Share

    April 2021
  318. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
    Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
    J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
    >> Share

  319. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
    Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
    J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
    >> Share

  320. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
    Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
    J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
    >> Share

  321. FAN L, Fei X, Zhu Y, Chi C, et al
    Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
    >> Share

  322. RAJWA P, Mori K, Huebner NA, Martin DT, et al
    The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
    >> Share

  323. STABILE A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, et al
    Association Between Lesion Location and Oncological Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
    J Urol. 2021 Apr 23:101097JU0000000000001787. doi: 10.1097/JU.0000000000001787.
    >> Share

  324. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Apr 21:101097JU0000000000001814. doi: 10.1097/JU.0000000000001814.
    >> Share

  325. ZHANG KW, Reimers MA, Calaway AC, Fradley MG, et al
    Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
    J Urol. 2021 Apr 19:101097JU0000000000001785. doi: 10.1097/JU.0000000000001785.
    >> Share

  326. LIN PH, Howard L, Freedland SJ
    Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
    J Urol. 2021 Apr 5:101097JU0000000000001780. doi: 10.1097/JU.0000000000001780.
    >> Share

  327. HALABI S, Jiang S, Terasawa E, Garcia-Horton V, et al
    Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    J Urol. 2021 Apr 5:101097JU0000000000001767. doi: 10.1097/JU.0000000000001767.
    >> Share

  328. MATSUMOTO K, Omura M, Takeda T, Kosaka T, et al
    Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade do Not Coincide within One Lesion.
    J Urol. 2021 Apr 5:101097JU0000000000001765. doi: 10.1097/JU.0000000000001765.
    >> Share

    March 2021
  329. BABAJIDE R, Carbunaru S, Nettey OS, Watson KS, et al
    Performance of Prostate Health Index in Biopsy Naive Black Men.
    J Urol. 2021;205:718-724.
    >> Share

  330. UMARI P, Eden C, Cahill D, Rizzo M, et al
    Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients.
    J Urol. 2021;205:780-790.
    >> Share

  331. TOSOIAN JJ, Trock BJ, Morgan TM, Salami SS, et al
    Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
    J Urol. 2021;205:732-739.
    >> Share

  332. MENG X, Chao B, Chen F, Huang R, et al
    Followup of Men with PI-RADS 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
    J Urol. 2021;205:748-754.
    >> Share

  333. FEUER Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, et al
    Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
    J Urol. 2021;205:740-747.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016